AstraZeneca's failed heart drug trial results trigger decline in Alnylam Pharmaceuticals stock

Shares of Alnylam dropped following AstraZeneca's announcement of full clinical trial results for a discontinued cardiovascular medication, impacting related biotech market sentiment.